The replication stress inflicted on retinal endothelial cells (ECs) in the context of hypoxia-induced pathological neovascularization during proliferative retinopathy is linked with activation of the deoxyribonucleic acid (DNA) repair response. Here, we studied the effect of deficiency of the DNA damage response adaptor 53BP1, which is an antagonist of homologous recombination (HR), in the context of proliferative retinopathy. In the model of retinopathy of prematurity (ROP), 53BP1-deficient mice displayed increased hypoxia-driven pathological neovascularization and tuft formation, accompanied by increased EC proliferation and reduced EC apoptosis, as compared with 53BP1-sufficient mice. In contrast, physiological retina angiogenesis was not affected by 53BP1 deficiency. Knockdown of 53BP1 in ECs in vitro also resulted in enhanced proliferation and reduced apoptosis of the cells under hypoxic conditions. Additionally, upon 53BP1 knockdown, ECs displayed increased HR rate in hypoxia. Consistently, treatment with an HR inhibitor reversed the hyper-proliferative angiogenic phenotype associated with 53BP1 deficiency in ROP. Thus, by unleashing HR, 53BP1 deletion increases pathological EC proliferation and neovascularization in the context of ROP. Our data shed light to a previously unknown interaction between the DNA repair response and pathological neovascularization in the retina.
1
Willis JR,
Doan QV,
Gleeson M.
, et al. Vision-related functional burden of diabetic retinopathy across severity levels in the United States. JAMA Ophthalmol 2017; 135 (09) 926-932
2
Sapieha P,
Joyal JS,
Rivera JC.
, et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest 2010; 120 (09) 3022-3032
3
VanderVeen DK,
Melia M,
Yang MB,
Hutchinson AK,
Wilson LB,
Lambert SR.
Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology 2017; 124 (05) 619-633
11
Okuno Y,
Nakamura-Ishizu A,
Otsu K,
Suda T,
Kubota Y.
Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat Med 2012; 18 (08) 1208-1216
13
Daley JM,
Sung P.
53BP1, BRCA1, and the choice between recombination and end joining at DNA double-strand breaks. Mol Cell Biol 2014; 34 (08) 1380-1388
14
Bunting SF,
Callén E,
Wong N.
, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141 (02) 243-254
16
Escribano-Díaz C,
Orthwein A,
Fradet-Turcotte A.
, et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell 2013; 49 (05) 872-883
18
Zong D,
Callén E,
Pegoraro G,
Lukas C,
Lukas J,
Nussenzweig A.
Ectopic expression of RNF168 and 53BP1 increases mutagenic but not physiological non-homologous end joining. Nucleic Acids Res 2015; 43 (10) 4950-4961
19
Ward IM,
Minn K,
van Deursen J,
Chen J.
p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol 2003; 23 (07) 2556-2563
21
Economopoulou M,
Avramovic N,
Klotzsche-von Ameln A.
, et al. Endothelial-specific deficiency of Junctional Adhesion Molecule-C promotes vessel normalisation in proliferative retinopathy. Thromb Haemost 2015; 114 (06) 1241-1249
24
Budke B,
Logan HL,
Kalin JH.
, et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 2012; 40 (15) 7347-7357
26
Aiba Y,
Kometani K,
Hamadate M.
, et al. Preferential localization of IgG memory B cells adjacent to contracted germinal centers. Proc Natl Acad Sci U S A 2010; 107 (27) 12192-12197
29
Fernandez-Capetillo O,
Celeste A,
Nussenzweig A.
Focusing on foci: H2AX and the recruitment of DNA-damage response factors. Cell Cycle 2003; 2 (05) 426-427
31
Ray Chaudhuri A,
Nussenzweig A.
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol 2017; 18 (10) 610-621
35
Ray Chaudhuri A,
Callen E,
Ding X.
, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 2016; 535 (7612): 382-387
